Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic sclerosis. Which therapies?].

L Bettoni1

  • 1Servizio di Immunologia Clinica, Spedali Civili, Brescia, Italy. ubbett@tin.it

Minerva Medica
|April 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheumatoid nodules: the importance of a correct differential diagnosis.

European annals of allergy and clinical immunology·2011
Same author

Influence of ethinyl estradiol on C1s inhibitor: a new etiopathogenetic mechanism of angioedema. Case report.

European annals of allergy and clinical immunology·2005
Same author

Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Clinical rheumatology·2002
Same author

Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients.

Clinical and experimental rheumatology·2001
Same author

Chilblain lupus erythematosus is associated with antibodies to SSA/Ro.

Lupus·1999
Same author

Isolated episodic lingual myoclonus.

European neurology·1999

Systemic sclerosis, a fibrotic connective tissue disease, requires timely, personalized therapy. Current treatments combine vasodilators, immunosuppressants, and antifibrotics for better patient outcomes.

Area of Science:

  • Rheumatology and Immunology
  • Pathophysiology of Fibrotic Diseases

Context:

  • Systemic sclerosis is a chronic connective tissue disease marked by excessive collagen deposition.
  • Fibrosis, an irreversible consequence of extracellular matrix accumulation, affects multiple organs including skin, lungs, heart, and kidneys.
  • Previous management strategies for systemic sclerosis have shown limited success.

Purpose:

  • To highlight the importance of new pathophysiological insights in managing systemic sclerosis.
  • To emphasize the need for timely and personalized therapeutic approaches.
  • To outline current drug management strategies for systemic sclerosis.

Summary:

  • Systemic sclerosis involves fibrosis and extracellular matrix accumulation in various organs.
  • Effective management necessitates a personalized therapy plan considering disease type, severity, and organ involvement.

Related Experiment Videos

  • Current drug regimens combine vasodilators (e.g., Prostaglandins), immunosuppressants (e.g., Cyclophosphamide), and antifibrotic agents (e.g., Penicillamine).

    • Impact:

    • Improved quality of life for patients with systemic sclerosis.
    • Enhanced global prognosis and reduced disability associated with systemic sclerosis.
    • Potential for more successful control of disease progression through tailored treatment.